Dr. Reddy's Receives Official DOJ Letter Closing FCPA Inquiry Without Action
Dr. Reddy's Laboratories has received formal confirmation from the US Department of Justice that its Foreign Corrupt Practices Act inquiry has been closed without any enforcement action recommended. The company disclosed this through regulatory filing, noting the DOJ letter dated March 5, 2026, which follows the SEC's similar conclusion in February 2026, effectively clearing the pharmaceutical company of the allegations that originated from an anonymous complaint in November 2020.
*this image is generated using AI for illustrative purposes only.
Dr. Reddy's Laboratories has received an official letter from the US Department of Justice confirming the closure of its Foreign Corrupt Practices Act inquiry without recommending any enforcement action. The pharmaceutical company disclosed this development through a formal regulatory filing, marking the conclusion of a multi-year investigation that began with an anonymous complaint.
Official DOJ Communication
The company received a letter dated March 5, 2026, from the US Department of Justice, Criminal Division, Fraud Section, formally stating that the Department has closed its inquiry under the Foreign Corrupt Practices Act. This official communication provides definitive closure to the regulatory matter that has been ongoing since the company's initial disclosure.
| Investigation Timeline: | Details |
|---|---|
| Initial Complaint: | November 19, 2020 |
| SEC Closure: | February 23, 2026 |
| DOJ Letter Date: | March 5, 2026 |
| Final Status: | No enforcement action recommended |
Investigation Background
The inquiry originated from an anonymous complaint regarding allegations of improper payments to healthcare professionals in Ukraine and potentially other countries. The company had proactively disclosed the matter to the DOJ, Securities and Exchange Commission, and Securities Exchange Board of India following the complaint. At the direction of the company's Board committee, Dr. Reddy's engaged a US law firm to conduct a detailed internal investigation.
Regulatory Clearance Process
The resolution represents a comprehensive regulatory clearance, with both major US regulatory bodies concluding their investigations. The SEC had previously informed the company through a letter dated February 23, 2026, that it had concluded its investigation and did not intend to recommend enforcement action. The DOJ's formal closure letter now completes the regulatory review process.
| Regulatory Status: | Outcome |
|---|---|
| US SEC Investigation: | Concluded without action |
| US DOJ FCPA Inquiry: | Closed without enforcement |
| Internal Investigation: | Completed |
| Regulatory Disclosure: | Filed under Regulation 30 |
Compliance and Operational Impact
The Foreign Corrupt Practices Act inquiry's closure without enforcement action validates the company's compliance practices and internal controls. For pharmaceutical companies operating in multiple international markets, FCPA compliance is particularly critical given complex regulatory environments and government interactions in the healthcare sector. This resolution removes regulatory uncertainty and allows the company to focus on its core pharmaceutical operations without the overhang of ongoing investigations.
19
